2. Academic Validation
  3. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma

  • Science. 2024 Jun 21;384(6702):eade8520. doi: 10.1126/science.ade8520.
Jaroslav Zak 1,  Isaraphorn Pratumchai 1 2,  Brett S Marro 1,  Kristi L Marquardt 1,  Reza Beheshti Zavareh 3,  Luke L Lairson 3,  Michael B A Oldstone 1,  Judith A Varner 4,  Livia Hegerova 5,  Qing Cao 6,  Umar Farooq 7,  Vaishalee P Kenkre 8,  Veronika Bachanova # 9,  John R Teijaro # 1
Affiliations

Affiliations

  • 1 Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
  • 2 Department of Immunology, Leiden University Medical Centre, Leiden, Netherlands.
  • 3 Department of Chemistry, The Scripps Research Institute, La Jolla, CA, USA.
  • 4 Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
  • 5 Division of Hematology, University of Washington School of Medicine, Seattle, WA, USA.
  • 6 Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
  • 7 Division of Hematology and Oncology and Bone Marrow Transplantation, University of Iowa, Iowa City, IA, USA.
  • 8 Division of Hematology/Oncology, University of Wisconsin, Madison, WI, USA.
  • 9 Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA.
  • # Contributed equally.
PMID: 38900864 DOI: 10.1126/science.ade8520
Abstract

Unleashing antitumor T cell activity by checkpoint inhibitor immunotherapy is effective in Cancer patients, but clinical responses are limited. Cytokine signaling through the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway correlates with checkpoint immunotherapy resistance. We report a phase I clinical trial of the JAK Inhibitor ruxolitinib with anti-PD-1 antibody nivolumab in Hodgkin lymphoma patients relapsed or refractory following checkpoint inhibitor immunotherapy. The combination yielded a best overall response rate of 53% (10/19). Ruxolitinib significantly reduced neutrophil-to-lymphocyte ratios and percentages of myeloid suppressor cells but increased numbers of cytokine-producing T cells. Ruxolitinib rescued the function of exhausted T cells and enhanced the efficacy of Immune Checkpoint blockade in preclinical solid tumor and lymphoma models. This synergy was characterized by a switch from suppressive to immunostimulatory myeloid cells, which enhanced T cell division.

Figures
Products